Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: The Fas counterattack

Diseases of the Esophagus

Volumn 12, Issue 2, 1999, Pages 83-89

  O'Connell, J ^a,b   Bennett, M W ^a   O'Sullivan, G C ^a   Collins, J K ^a   Shanahan, F ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b University College Cork and INFANT Centre   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND; PROTEIN BCL 2;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; APOPTOSIS; B LYMPHOCYTE; DOWN REGULATION; ESOPHAGUS CANCER; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOREGULATION; LYMPHOID CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANTIGENS, CD95; APOPTOSIS; ESOPHAGEAL NEOPLASMS; FAS LIGAND PROTEIN; HUMANS; LYMPHOCYTE SUBSETS; LYMPHOCYTES, TUMOR-INFILTRATING; MEMBRANE GLYCOPROTEINS; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 0032777209     PISSN: 11208694     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2050.1999.00033.x     Document Type: Review

References (51)

1. Quillien V, Raoul J, Heresbach D, Collet B, Toujas L, Brasseur F. Expression of MAGE genes in esophageal squamous-cell carcinoma. Anticancer Res 1997; 17: 387-391.
2. Turner J R, Odze R D, Crum C P, Resnick M B. MN antigen expression in normal, preneoplastic, and neoplastic esophagus: a clinicopathological study of a new cancer-associated biomarker. Hum Pathol 1997; 28: 740-744.
3. Kudo T, Kobayashi S, Murakami K et al. A novel human monoclonal antibody directed to a tumor-associated antigen. Jpn J Cancer Res 1993; 84: 760-769.
4. Wang R F, Johnston S L, Zeng G et al. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J Immunol 1998; 161: 3598-3606.
5. Nakao M, Yamana H, Imai Y et al. HLA A2601-restricted CTLs recognize a peptide antigen expressed on squamous cell carcinoma. Cancer Res 1995; 55: 4248-4252.
6. Toh U, Yamana H, Nakao M et al. HLA class I-restricted and tumor-specific cytotoxic T lymphocytes from metastatic lymph nodes of esophageal cancers. Cell Immunol 1997; 177: 137-143.
7. Rockett J, Darnton S, Crocker J, Matthews H, Morris A. Expression of HLA-ABC, HLA-DR and intercellular adhesion molecule-1 in oesophageal carcinoma. J Clin Pathol 1995; 48: 539-544.
8. Hosch S B, Izbicki J R, Pichlmeier U et al. Expression and prognostic significance of immunoregulatory molecules in esophageal cancer. Int J Cancer 1997; 74: 582-587.
9. O'Mahony A M, O'Sullivan G C, O'Connell J, Cotter T G, Collins J K. An immune suppressive factor derived from esophageal squamous carcinoma induces apoptosis in normal and transformed cells of lymphoid lineage. J Immunol 1993; 151: 4847-4856.
10. O'Sullivan G C, Corbett A R, Shanahan F, Collins J K. Regional immunosuppression in esophageal squamous cancer: evidence from functional studies with matched lymph nodes. J Immunol 1996; 157: 4717-4720.
11. Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449-1456.
12. Lynch D H, Ramsdell F, Alderson M R. Fas and FasL in the homeostatic regulation of immune responses. Immunol Today 1995; 16: 569-574.
13. Griffith T S, Brunner T, Fletcher S M, Green D R, Ferguson T A. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189-1192.
14. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke R C. A role for CD95 ligand in preventing graft rejection. Nature 1995; 377: 630-632.
15. Saas P, Walker P R, Hahne M et al. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest 1997; 99: 1173-1178.
16. Hunt J S, Vassmer D, Ferguson T A, Miller L. Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus. J Immunol 1997; 158: 4122-4128.
17. Stuart P M, Griffith T S, Usui N, Pepose J, Yu X, Ferguson T A. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J Clin Invest 1997; 99: 396-402.
18. Korbutt G S, Elliott J F, Rajotte R V. Cotransplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression. Diabetes 1997; 46: 317-322.
19. Lau H T, Yu M, Fontana A, Stoeckert C J J. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 1996; 270: 109-112.
20. Gainer A L, Suarez-Pinzon W L, Min W P et al. Improved survival of biolistically transfected mouse islet allografts expressing CTLA4-Ig or soluble Fas ligand. Transplantation 1998; 66: 194-199.
21. Li X K, Okuyama T, Tamura A et al. Prolonged survival of rat liver allografts transfected with Fas ligand-expressing plasmid. Transplantation 1998; 66: 1416-1423.
22. Swenson K M, Ke B, Wang T et al. Fas ligand gene transfer to renal allografts in rats: effects on allograft survival. Transplantation 1998; 65: 155-160.
23. Allison J, Georgiou H M, Strasser A, Vaux D L. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc Natl Acad Sci USA 1997; 94: 3943-3947.
24. Kang S-M, Schneider D B, Lin Z et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nature Med 1997; 3: 738-743.
25. Seino K, Kayagaki N, Okumura K, Yagita H. Antitumor effect of locally produced CD95 ligand. Nature Med 1997; 3: 165-170.
26. Miwa K, Asano M, Horai R, Iwakura Y, Nagata S, Suda T. Caspase 1-independent IL-1β release and inflammation induced by the apoptosis inducer Fas ligand. Nature Med 1998; 4: 1287-1292.
27. Lau H T, Stoeckert C J. FasL - too much of a good thing? Nature Med 1997; 3: 727-728.
28. Chen J-J, Sun Y, Nabel G J. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 1998; 282: 1714-1717.
29. O'Connell J, O'Sullivan G C, Collins J K, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184: 1075-1082.
30. O'Connell J, Bennett M W, O'Sullivan G C, Collins J K, Shanahan F. The Fas counterattack: a molecular mechanism of tumor immune privilege. Mol Med 1997; 3: 294-300.
31. O'Connell J, Bennett M W, O'Sullivan G C et al. Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer. J Pathol 1998; 186: 240-246.
32. Hahne M, Rimoldi D, Schroter M et al. Melanoma cell expression of Fas(APO-1/CD95) ligand: implications for tumor immune escape. Science 1996; 274: 1363-1366.
33. Strand S, Hofmann W J, Hug H et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nature Med 1996; 2: 1361-1366.
34. Niehans G A, Brunner T, Frizelle S P et al. Human lung carcinomas express Fas ligand. Cancer Res 1997; 57: 1007-1012.
35. Khar A, Varalakshmi C, Pardhasaradhi B V V, Mubarak Ali A, Kumari A L. Depletion of the natural killer cell population in the peritoneum by AK-5 tumor cells overexpressing Fas ligand: a mechanism of immune evasion. Cell Immunol 1998; 189: 85-91.
36. O'Connell J, Bennett M W, O'Sullivan G C, Collins J K, Shanahan F. The Fas counterattack: cancer as a site of immune privilege. Immunol Today 1999; 20: 46-52.
37. Gratas C, Tohma Y, Barnas C, Taniere P, Hainaut P, Ohgaki H. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Cancer Res 1998; 58: 2057-2062.
38. Bennett M W, O'Connell J, O'Sullivan G C et al. The Fas counterattack in vivo: apoptotic depletion of tumorinfiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 1998; 160: 5669-5675.
39. Daniel P T, Kroidl A, Cayeux S, Bargou R, Blankenstein T, Dorken B. Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis. J Immunol 1997; 159: 3808-3815.
40. Rabinowich H, Reichert T E, Kashii Y, Gastman B R, Bell M C, Whiteside T L. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. J Clin Invest 1998; 101: 2579-2588.
41. Mulder W M C, Bloemena E, Stukart M J, Kummer J A, Wagstaff J, Scheper R J. T cell receptor-ζ and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma. Gut 1997; 40: 113-119.
42. Cascino I, Fiucci G, Papoff G, Ruberti G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol 1995; 154: 2706-2713.
43. Hughes S J, Nambu Y, Soldes O S et al. Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma. Cancer Res 1997; 57: 5571-5578.
44. Ossina N K, Cannas A, Powers V C et al. Interferon-gamma modulates a p53-independent apoptotic pathway and apoptosis-related gene expression. J Biol Chem 1997; 272: 16351-16357.
45. Tamura T, Ueda S, Yoshida M, Matsuzaki M, Mohri H, Okubo T. Interferon-gamma induces ICE gene expression and enhances cellular susceptibility to apoptosis in the U937 leukemia cell line. Biochem Biophys Res Commun 1996; 229: 21-26.
46. Sarbia M, Bittinger F, Porschen R et al. Bc1-2 expression and prognosis in squamous-cell carcinomas of the esophagus. Int J Cancer 1996; 69: 324-328.
47. Krajewski S, Krajewska M, Reed J C. Immunohistochemical analysis of in vivo patterns of Bak expression, a proapoptotic member of the Bc1-2 protein family. Cancer Res 1996; 56: 2849-2855.
48. Katada N, Hinder R A, Smyrk T C et al. Apoptosis is inhibited early in the dysplasia-carcinoma sequence of Barrett esophagus. Arch Surg 1997; 132: 728-733.
49. Torzewski M, Sarbia M, Heep H, Dutkowski P, Willers R, Gabbert H E. Expression of Bc1-X (L), an antiapoptotic member of the Bc1-2 family, in esophageal squamous cell carcinoma. Clin Cancer Res 1998; 4: 577-583.
50. Ohashi K, Nemoto T, Eishi Y, Matsuno A, Nakamura K, Hirokawa K. Proliferative activity and p53 protein accumulation correlate with early invasive trend, and apoptosis correlates with differentiation grade in esophageal squamous cell carcinomas. Virchows Arch 1997; 430: 107-115.
51. Watson A J, Merritt A J, Jones L S et al. Evidence of reciprocity of bc1-2 and p53 expression in human colorectal adenomas and carcinomas. Br J Cancer 1996; 73: 889-895.